

3404 Cooney Drive, Helena, MT 59602  
 Phone 406.443.6002 • Toll Free Phone 1.800.395.7961  
 Fax 406.513.1928 • Toll Free Fax 1.800.294.1350

## Montana Medicaid Prior Authorization Request for Hepatitis C Treatment

**Note: Forms completed by the providing pharmacy will not be accepted. Forms must be completed by the prescribing office.**

Patient's Name:	Patient's Medicaid ID#:
Patient's DOB:	Today's Date:
Hep C Provider's Name:	Hep C Provider's Specialty: (Infectious Disease/Gastroenterology/Hepatology)- <b>required</b>
Hep C Provider's Phone #:	Hep C Provider's Fax #:
Which provider referred patient to you?:	
Who is patient's primary care provider?:	
Who is patient's mental health provider (if applicable)?:	
<b>Requested Drug Regimen and Total Treatment Duration:</b>	

**I. Patient Readiness Criteria (Check boxes indicate patient/provider acknowledgment):**

Patient psychosocial readiness is a critical component for Hepatitis C treatment success. It is important that any potential impediments to the effectiveness of treatment have been identified and that a plan for dealing with these impediments has been developed. The patient must be educated that abuse of alcohol may cause further liver damage and that abuse of IV injectable drugs may increase the risk of re-infection of Hepatitis C if the virus is cleared. Given the high cost of Hepatitis C treatment, we want to ensure that both the provider and the patient feel that the patient is committed to effectively start and successfully adhere to treatment.

- Patient must not have a history of alcohol abuse, injectable drug abuse, and/or other controlled-substance abuse for at least 6 months prior to approval of Hepatitis C treatment. Patient involvement in a support group or counseling is highly encouraged for successful abstinence.
- Patient must be compliant with all current medications that are being prescribed for all disease states/conditions to be considered eligible for Hepatitis C treatment approval.
- Patient must have a history of compliance with scheduled appointments/labs preceeding approval of Hepatitis C treatment.
- If patient has mental health conditions, patient must be compliant with mental health medications and/or psychotherapy. If patient has mental health conditions that are not currently being treated, then a mental health consult to assess for patient readiness will be required before Hepatitis C treatment can begin.

**Patient signature (required):** \_\_\_\_\_ **Date:** \_\_\_\_\_

## Clinical Requirements:

Attach all supporting documentation.

### A. Hepatitis C Virus Assessment:

- Hepatitis C Genotype (and subtype if applicable): \_\_\_\_\_
- Current quantitative HCV RNA results are attached.

### B. Liver Assessment:

\*Note: Approval is currently limited to F3 or F4 liver fibrosis staging.

1. Liver Fibrosis Stage: F0 F1 F2 F3 F4
2. If F4 (cirrhotic), determine the Child Pugh Grade:

Assessment Parameter	Possible Points			Points Assigned
	1	2	3	
1. Ascites	Absent	Slight	Moderate	
2. Bilirubin, total (mg/dL)	1.0-2.0	2.0-3.0	>3.0	
3. Albumin (g/dL)	>3.5	2.8-3.5	<2.8	
4. Prothrombin Time -Seconds prolonged OR -International normalized ratio (INR)	1.0-4.0 <1.7	4.0-6.0 1.7-2.3	>6.0 >2.3	
5. Encephalopathy Grade 0-no abnormality detected 1-shortened attention span, impaired addition & subtraction skills, mild euphoria/anxiety 2-Lethargy, apathy, disoriented to time, personality change, inappropriate behavior 3-Somnolence, semi-stupor, responsive to stimuli, confused when awake, gross disorientation 4-Coma, little or no response to stimuli, mental state not testable	None	Grade 1-2	Grade 3-4	
<b>Total</b>				

Adapted from: Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646-9. PMID.

**Child Pugh Grade** (as determined from total points):

- Child Pugh A (Mild; **Compensated cirrhosis** = 5-6)
- Child Pugh B (Moderate; Significant functional compromise; **Decompensated cirrhosis** = 7-9)
- Child Pugh C (Severe; **Decompensated cirrhosis** = 10-15)

3. Does patient have any *severe* extrahepatic manifestations? Yes No

If yes, please describe: \_\_\_\_\_  
\_\_\_\_\_

### C. Patient History:

- Prescribing specialist chart notes are attached (prescriber must continue to monitor patient throughout treatment course).
- List any previously tried Hepatitis C treatments, dates treated, and response:  
\_\_\_\_\_
- List any over-the-counter medications or nutritional/herbal supplements that patient is currently taking:  
\_\_\_\_\_  
\_\_\_\_\_

**D. Required Labs (attached):**

- Hepatitis C Genotype (and subtype if applicable)
- HCV RNA viral load
- FibroSure/FibroTest, Fibroscan or liver biopsy report
- CMP
- CBC
- Liver panel (including AST, ALT, direct bilirubin, total bilirubin, and alkaline phosphatase).
- INR

**II. Authorization Limitations:**

1. Approval is subject to Montana Medicaid Preferred Drug List (PDL) requirements.
2. Approval will be granted per FDA-approved labeling for each individual drug (dose and duration of treatment).
3. Medication compliance is essential for successful treatment. Provider attests that patient will be monitored throughout therapy for compliance and safety.

**Provider's Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Please complete form, attach documentation, and fax to:  
Medicaid Drug Prior Authorization Unit at 1-800-294-1350**